Imagine a pen-size spray powerful enough to kill 60 pathogens, yet gentle enough for your eyes, nose and mouth. Union Pharmaceuticals, based in Erlanger, has marketed this product to law enforcement, corrections, and other professional fields. And starting in November, MyClyns Personal Spray will be available to the general public.
Joel Ivers, president of Union Pharmaceuticals, notes the timely nature of the product's roll-out.
"The swine flu epidemic has created awareness of the need for germ protection. But our product is generally applicable." Ivers named MRSA and E.Coli as two of the germs that MyClyns will inactivate on contact, preventing the body from absorbing the pathogen.
MyClyns was originally conceived as a "pre-hospital," emergency medicine product. But Ivers has watched its popularity grow. "We guessed that people would find other settings for MyClyns. Once there was proof of the concept, we (knew we) would ultimately make it a consumer product."
The track record of Ivers' company is equally powerful. Started in Jaunary of 2008, Union Pharmaceuticals now sells its products in 35 countries. MyClyns is manufactured in Louisville; the company headquarters recently moved to a new space near Cincinnati/Northern Kentucky International Airport.
Biggs was the first local chain to order MyClyns, but Ivers expects many other chains to quickly follow suit. Suggested retail price is $9.99 for 6 mL.
MyClyns has potential for a critical impact on community and personal health. Ivers explains, "We keep our hands clean to not transfer germs into our body. [Union Phramaceuticals] is providing a product to inactivate germs, right where they enter the body. In case you accidentally touch or breathe in a pathogen, it's an extra line of defense."
Writer: Elena Stevenson
Source: Joel Ivers, President, Union Pharmaceuticals, www.uspharma.com
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.